Literature DB >> 2454376

A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.

W J Louis1, J J McNeil, B S Workman, O H Drummer, E L Conway.   

Abstract

This study in eight elderly male volunteers examined the pharmacokinetics of carvedilol following intravenous and oral administration of the drug. Blood pressure and pulse rate responses were also determined and compared with those to labetalol. Carvedilol was absorbed rapidly after oral administration with a bioavailability of approximately 45% and obeyed linear pharmacokinetics over the dose range 25-50 mg. The terminal elimination half-life varied between 5 and 14 h. Administration of the drug with food did not alter the bioavailability or kinetic handling of carvedilol. The hemodynamic responses to carvedilol followed the same pattern as those to labetalol. There was a rapid dose-related fall in blood pressure maximal after 4-5 h and disappearing by 12 hours. Tachycardia that was evident on placebo was inhibited by both drugs. Postural hypotension and dizziness were also apparent with both drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2454376

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.

Authors:  B K Krämer; K M Ress; C M Erley; T Risler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

4.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

5.  Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers.

Authors:  Stefanie A Fahlbusch; Dimitrios Tsikas; Christina Mehls; Frank-Mathias Gutzki; Rainer H Böger; Jürgen C Frölich; Dirk O Stichtenoth
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

7.  The use of carvedilol in elderly hypertensive patients.

Authors:  T O Morgan; A Anderson; J Cripps; W Adam
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Carvedilol: a review of its use in chronic heart failure.

Authors:  Gillian M Keating; Blair Jarvis
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.